- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02701439
SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting (PTB)
Small Membrane Filtration (SMF) Method to Improve the Performance of Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting
Studieoversikt
Detaljert beskrivelse
TB is a disease caused by a bacterium called Mycobacterium tuberculosis that can affect the lungs or other parts of the body. In most of the world and in Mbarara, Uganda, the method of diagnosis that is used is AFB smear microscopy. This method is widely available, inexpensive and rapid. However, this method's ability to truly detect people having TB is poor. That is, if someone has TB, the test results may say that they are negative, leading to delays in diagnosis, disease progression, and an ongoing transmission of the bacteria.
The new test for TB diagnosis we are studying is called the Small Membrane Filtration (SMF) method. This test that is being compared to the method currently being used and is very similar to the one that is currently used (standard smear microscopy) but has the advantage of concentrating the sputum (mucus) so that we can more easily see if bacteria are present in the sputum. It is hoped that a better way of knowing if someone has TB will help doctors decide when people need to be treated for TB and when not, which will improve the health of patients and help avoid passing the infection to others.
This study will enroll 740 HIV-infected and 310 HIV-uninfected adults with culture confirmed pulmonary TB. These individuals will be identified prospectively at two TB clinics in Mbarara, Uganda.
Study hypothesis: The investigators will assume that one sputum sample will be equivalent to two (null hypothesis) with respect to sensitivity unless we have evidence that the use of two has higher sensitivity (alternative hypothesis). The investigators will assume that SMF is equivalent to AFB smear with respect to sensitivity and specificity unless the investigators find evidence it is superior. The investigators will assume that SMF is equivalent to Xpert unless the investigators find evidence that Xpert is superior.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Mbarara, Uganda, 1956
- Epicentre Mbarara Research Base
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Adult (≥18 years)
- Pulmonary TB suspect defined as any person who presents with a productive cough for more than 2 weeks AND accompanied by at least one other respiratory symptom (shortness of breath, chest pains, hemoptysis) and/or constitutional symptom (loss of appetite, weight loss, fever, night sweats, and fatigue) (6).
- Willing to undergo TB evaluation and spontaneously expectorate ≥2 mL of sputum
- Willing to be tested for HIV, if no results available within past 6 months
Exclusion Criteria:
- Too ill or unable to provide written consent
- Treated with TB drugs for more than 3 days
- Extra-pulmonary or disseminated TB without pulmonary involvement (i.e. no cough)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tidsperspektiver: Tverrsnitt
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
HIV-infected
Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB. Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
|
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
|
HIV negative
Enrollment of 350 HIV negative adults with suspicion of pulmonary TB. Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
|
Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Sensitivity and specificity of SMF method and Xpert MTB/RIF assay
Tidsramme: 24 months
|
The primary endpoints of this laboratory-based study will be to determine the sensitivity and specificity of the SMF method and Xpert MTB/RIF assay, using manual MGIT liquid culture as the gold standard
|
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Yap Boum II, PhD, Epicentre
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SMF-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tuberkulose
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... og andre samarbeidspartnereRekrutteringTuberkulose | Mycobacterium TuberculosisSveits
-
National Institute of Allergy and Infectious Diseases...FullførtMycobacterium TuberculosisBrasil
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)FullførtMycobacterium TuberculosisForente stater, Colombia, Mexico
-
Johns Hopkins UniversityAvsluttetMycobacterium TuberculosisForente stater
-
National Institute of Allergy and Infectious Diseases...Fullført
-
National Institute of Allergy and Infectious Diseases...Fullført
-
Region SkaneRekrutteringLatent tuberkulose | Mycobacterium Tuberculosis | Vedvarende infeksjonSverige
-
François SpertiniUniversity of OxfordFullførtTuberkulose | Mycobacterium Tuberculosis, beskyttelse motSveits
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktiv, ikke rekrutterendeMycobacterium Tuberculosis-infeksjonGabon, Kenya, Sør-Afrika, Tanzania, Uganda
-
Johns Hopkins UniversityUnited States Agency for International Development (USAID)Har ikke rekruttert ennåTuberkulose | Tuberkulose, lunge | Mycobacterium Tuberculosis | Tuberkulose, lymfeknuteUganda, Sør-Afrika, Mosambik, Indonesia, Zambia
Kliniske studier på Small membrane filtration
-
NHS Greater Glasgow and ClydeUniversity of GlasgowFullførtDiabetes mellitus, type 2 | Vekt styringStorbritannia
-
Shanghai General Hospital, Shanghai Jiao Tong University...Duke University; Rutgers University; Tsinghua UniversityFullførtIkke-røykere, sunne voksneKina
-
The Hong Kong Polytechnic UniversityHar ikke rekruttert ennå
-
University of AarhusAarhus University Hospital; Aalborg University Hospital; Qufora A/SFullførtFekal inkontinens | Forstoppelse - FunksjonellDanmark
-
Gruppo Italiano per la Valutazione degli Interventi...BELLCO S.r.l., Mirandola (MO), ITALYAvsluttet
-
Paragon 28Avsluttet
-
National Cancer Centre, SingaporeFullførtSkjoldbrusk sykdommerSingapore
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.MediBeaconFullførtNyresykdommer | Nyreskade | NyresviktKina
-
MediBeaconRekrutteringNyresykdommer | Nyreskade | NyresviktForente stater
-
MediBeaconFullført